A distinct metabolic signature of human colorectal cancer with prognostic potential

Yunping Qiu, Guoxiang Cai, Bingsen Zhou, Dan Li, Aihua Zhao, Guoxiang Xie, Houkai Li, Sanjun Cai, Dong Xie, Changzhi Huang, Weiting Ge, Zhanxiang Zhou, Lisa X. Xu, Weiping Jia, Shu Zheng, Yun Yen, Wei Jia

研究成果: 雜誌貢獻文章

67 引文 (Scopus)

摘要

Purpose: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. Experimental Design: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. Results: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. Conclusions: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential.
原文英語
頁(從 - 到)2136-2146
頁數11
期刊Clinical Cancer Research
20
發行號8
DOIs
出版狀態已發佈 - 四月 15 2014
對外發佈Yes

指紋

Metabolomics
Colorectal Neoplasms
Biomarkers
Geographic Locations
Neoplasms
Clinical Protocols
Gas Chromatography
China
Mass Spectrometry
Oxidative Stress
Research Design
Survival Rate
Cell Proliferation
Gene Expression
Recurrence
Drug Therapy
Mutation
Enzymes
Growth
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

引用此文

A distinct metabolic signature of human colorectal cancer with prognostic potential. / Qiu, Yunping; Cai, Guoxiang; Zhou, Bingsen; Li, Dan; Zhao, Aihua; Xie, Guoxiang; Li, Houkai; Cai, Sanjun; Xie, Dong; Huang, Changzhi; Ge, Weiting; Zhou, Zhanxiang; Xu, Lisa X.; Jia, Weiping; Zheng, Shu; Yen, Yun; Jia, Wei.

於: Clinical Cancer Research, 卷 20, 編號 8, 15.04.2014, p. 2136-2146.

研究成果: 雜誌貢獻文章

Qiu, Y, Cai, G, Zhou, B, Li, D, Zhao, A, Xie, G, Li, H, Cai, S, Xie, D, Huang, C, Ge, W, Zhou, Z, Xu, LX, Jia, W, Zheng, S, Yen, Y & Jia, W 2014, 'A distinct metabolic signature of human colorectal cancer with prognostic potential', Clinical Cancer Research, 卷 20, 編號 8, 頁 2136-2146. https://doi.org/10.1158/1078-0432.CCR-13-1939
Qiu, Yunping ; Cai, Guoxiang ; Zhou, Bingsen ; Li, Dan ; Zhao, Aihua ; Xie, Guoxiang ; Li, Houkai ; Cai, Sanjun ; Xie, Dong ; Huang, Changzhi ; Ge, Weiting ; Zhou, Zhanxiang ; Xu, Lisa X. ; Jia, Weiping ; Zheng, Shu ; Yen, Yun ; Jia, Wei. / A distinct metabolic signature of human colorectal cancer with prognostic potential. 於: Clinical Cancer Research. 2014 ; 卷 20, 編號 8. 頁 2136-2146.
@article{ba471182dbbf48a29850ab416f215a30,
title = "A distinct metabolic signature of human colorectal cancer with prognostic potential",
abstract = "Purpose: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. Experimental Design: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. Results: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. Conclusions: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential.",
author = "Yunping Qiu and Guoxiang Cai and Bingsen Zhou and Dan Li and Aihua Zhao and Guoxiang Xie and Houkai Li and Sanjun Cai and Dong Xie and Changzhi Huang and Weiting Ge and Zhanxiang Zhou and Xu, {Lisa X.} and Weiping Jia and Shu Zheng and Yun Yen and Wei Jia",
year = "2014",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-13-1939",
language = "English",
volume = "20",
pages = "2136--2146",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A distinct metabolic signature of human colorectal cancer with prognostic potential

AU - Qiu, Yunping

AU - Cai, Guoxiang

AU - Zhou, Bingsen

AU - Li, Dan

AU - Zhao, Aihua

AU - Xie, Guoxiang

AU - Li, Houkai

AU - Cai, Sanjun

AU - Xie, Dong

AU - Huang, Changzhi

AU - Ge, Weiting

AU - Zhou, Zhanxiang

AU - Xu, Lisa X.

AU - Jia, Weiping

AU - Zheng, Shu

AU - Yen, Yun

AU - Jia, Wei

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Purpose: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. Experimental Design: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. Results: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. Conclusions: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential.

AB - Purpose: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. Experimental Design: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. Results: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. Conclusions: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=84899020281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899020281&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-1939

DO - 10.1158/1078-0432.CCR-13-1939

M3 - Article

C2 - 24526730

AN - SCOPUS:84899020281

VL - 20

SP - 2136

EP - 2146

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -